• Nem Talált Eredményt

Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s Programmes at the University of Pécs and at the University of Debrecen

N/A
N/A
Protected

Academic year: 2022

Ossza meg "Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s Programmes at the University of Pécs and at the University of Debrecen"

Copied!
28
0
0

Teljes szövegt

(1)

Manifestation of Novel Social Challenges of the European Union in the Teaching Material of

Medical Biotechnology Master’s Programmes

at the University of Pécs and at the University of Debrecen

Identification number: TÁMOP-4.1.2-08/1/A-2009-0011

(2)

POLYPHARMACY

(POLYPRAGMASIA) IN THE ELDERLY

Gyula Bakó and Miklós Székely

Molecular and Clinical Basics of Gerontology – Lecture 20

Manifestation of Novel Social Challenges of the European Union in the Teaching Material of

Medical Biotechnology Master’s Programmes

at the University of Pécs and at the University of Debrecen

Identification number: TÁMOP-4.1.2-08/1/A-2009-0011

(3)

Specific therapeutic challenge of prescribing for the elderly

Principle factors:

I Multiple and severe illnesses – Multiple drug therapy

Drug use in the elderly is disproportionately high:

patients over 65 constitute 12% of the US

population and consume 31% of prescribed drugs secondary to:

• increased severity of chronic illnesses

• presence of multiple pathologies

• excessive prescribing.

II Poor adherence to medication regimens

III Altered pharmacokinetics and pharmacodynamics

(4)

The most common chronic diseases in

which the elderly need more medications

Cardiovascular diseases:

• angina pectoris

• cardiac failure

• hypertension

• atrial fibrillation

Neurological diseases:

• cerebral hemorrhage

• Parkinson’s disease Psychiatric disorders:

• dementia

• depression

• confusion

Urological disorders:

• urinary incontinence

Musculoskeletal disorders:

• arthritis

• arthrosis

• osteoporosis

Endocrinological disorders:

• thyroid diseases

Gastrointestinal diseases:

• constipation

• GERD

(5)

Prevalence of multimorbidity

Using 24 major diagnostic categories…

• 82 percent of people aged 65 and older had one or more chronic conditions

• 65 percent had two or more

• 43 percent had three or more

• 24 percent had four or more.

On average there are 2.3

chronic conditions reported by people aged 65 and older.

Wolff JL, Starfield B, Anderson G. Arch Intern Med. 2002;162:2269-2276 0

10 20 30 40 50 60 70 80 90

1 or more 2 or more 3 or more 4 or more

(6)

Polypharmacy for the elderly Vienna study

Number of agents and their distribution depending on the patients’ age

Age cohort Percentage of patient on all insured person

0 5 10 15 20 25 30 35 40

61 to 70 years 71 to 80 years 81 to 90 years 91 years or older

Active substances: 1 – 4 5 – 8 9 – 12 13 or more

(7)

Polypharmacy for the elderly: a

representative sample from Hungary

The distribution of the frequency (%) in fuction of the number of therapeutic agents.

Drug consumption

0%1% 6% 11% 11% 14% 11% 10% 11% 6% 19%

6% 4% 7% 10% 8% 15% 10% 10% 7% 5% 17%

0%

5%

10%

15%

20%

0 1 2 3 4 5 6 7 8 9 10<

pill/person/day

Percentage of the participants

health care social institution

(8)

TÁMOP-4.1.2-08/1/A-2009-0011

Why are so many elderly patients using a lot of drugs

inappropriately?

Factors depending on the patient:

• Chronic diseases requiring long-term treatment become more common.

• Atypical presentation of diseases.

• Expectations of both the family and the patient (people keep going to see the doctor until they get what they want).

• There is no satisfactory doctor-patient relationship in time or in depth because of the crowded outpatient services.

• The elderly often take OTCs (over-the-counter drugs) about which the doctor is not informed.

• Due to the uncertain origin of the drugs (from friends,

relatives, and commercials), side effects and interactions can appear.

(9)

TÁMOP-4.1.2-08/1/A-2009-0011

Why are so many elderly patients using a lot of drugs

inappropriately?

Factors depending on the physician:

• The treatment is frequently focused on the symptoms: one additional symptom – one additional drug.

• An additional drug is given to correct an existing side-effect.

• Lack of personalized care: multiple parallel drug prescriptions are subscribed by different doctors.

• The control of drug efficacy is also missing.

(10)

Physiological and pathophysiological changes in the elderly influencing drug effects

1 reduced body weight*

2 decreased muscle mass 3 reduced total body water

4 increased (later decreased) mass of adipose tissue 5 decreased mass of plasma proteins

6 reduced stroke volume 7 impaired kidney functions

8 reduced weight and blood flow of liver 9 reduced amount of certain hormones

*The decrease in body weight is due to decreased bone mass and due to causes under #2-3.

(11)

Physiological and pathophysiological changes in the elderly influencing drug effects

The listed changes generally develop with aging, however, they differ individually on a case by case basis.

The degree of these changes is different and it is

difficult to determine to what extent the changes can

be considered physiological.

(12)

Age-dependent

basic pharmacological alterations of the elderly

Pharmacokinetics Pharmacodynamics

Altered pharmacokinetics and

pharmacodynamics

(13)

Pharmacokinetics in the elderly

1 ABSORPTION

2 TRANSPORT

3 DISTRIBUTION

4 METABOLISM

5 ELIMINATION

(14)

Pharmacokinetics in the elderly:

absorption

Aging-associated changes:

• The pH in the stomach is closer to neutral.

• Longer transition time in the GI system.

• Decreased surface of the small intestine.

• Diminished blood perfusion (GI, transdermal etc. absorption).

Consequences:

• Delayed absorption as indicated by a smaller and delayed peak plasma level. The area under curve (AUC*) hardly changes.

• Decreased first-pass effect after oral administration.

• Overall bioavailability remains maintained (slower excretion!). Though numerous structural and physiological age-related changes in the GI tract exist, they are of minimal clinical significance in the absence of

gastrointestinal pathology.

* The area under the curve depicting changes in concentration over time is

proportionate with the overall amount of absorbed drug, irrespective of the speed of absorption.

(15)

Pharmacokinetics in the elderly:

transport

Aging-associated changes:

• Decrease in the albumin concentration (by 10%).

Consequences:

• Free plasma drug level increases by about 10%

(medication with narrow therapeutic range, e.g.

digoxin);

• In case of simultaneous administration of multiple drugs, the rate of binding to transporter molecules becomes unpredictable:  side effects,  drug

interactions. (e.g. coumarins, theophylline, salicylates)

•  unexpected drug toxicity !

(16)

Pharmacokinetics in the elderly:

distribution

Aging-associated changes:

• Both the total body water and the distribution volume of water soluble drugs decrease (by about 10-15%).

• The amount of the adipose tissue and the distribution volume of lipid soluble drugs increase (by about 20%).

• Although the fat content is higher in women than in men, the

relative change in the volume of distribution for lipophilic drugs is more marked in men than in women (18 to 36% in men, 33 to 45%

in women).

Consequences:

• Concentration of water soluble drugs increases (e.g. lithium,

vancomycin). Diuretics and insufficient water intake may lead to enhanced (toxic) drug effects (e.g. aminoglycosides,

antiarrhythmic drugs, digoxin, lidocain, theophylline)!

• Underdose of fat soluble drugs (e.g. benzodiazepines).

(17)

Pharmacokinetics in the elderly:

distribution in very old people

• Very old individuals loose weight and become frail, the

proportion of fat decreases so that the volume of distribution for lipophilic drugs again decreases and the serum

concentrations increase.

• The frailty of very old individuals tends to be overlooked, low weight patients on average receive higher doses per unit

body weight than heavier patients. Hence, low body weight, in addition to advanced age, constitutes a risk factor for

overmedication.

(18)

Pharmacokinetics in the elderly:

metabolism

Aging-associated changes:

• The weight of the liver (by about 25-35%) and the hepatic blood flow (by about 30-40 %) decrease.

• The rate of hepatic drug clearance is impaired.

Consequences:

• Increased risk for impaired liver function is seen in exsiccosis and chronic heart failure!

• Decrease in hepatic blood flow is often associated

with decreased first pass effect.

(19)

Pharmacokinetics in the elderly:

elimination

Aging-associated changes:

• Elimination (excretion) through the liver is usually minimally reduced.

• Kidney functions are impaired due to - decrease in glomerular filtration rate

- reduced tubular functions (fibrosis, atrophy).

Consequences:

• Toxic effects of drugs eliminated via the kidney may increase (e.g. amikacin, amiloride, ciprofloxacin,

digoxin, enalapril, furosemide, gentamycin,

hydrochlorothiazide, vancomycin)!

(20)

Pharmacodynamic changes in the elderly

Responsiveness of the body changes with age:

• Changes in the blood-brain barrier

• Alteration in receptor properties - affinity

- number

- post-receptor response (enhanced/diminished)

• Homeostatic changes: decreased capacity to respond to physiological challenges and to the adverse side effects of drug therapy (e.g. baroreceptors).

Cell-tissue response to a drug may be changed concerning the

• mechanism,

• intensity,

• peak,

• duration of physiological actions.

(21)

Pharmacodynamic changes in the elderly: increased responsiveness

Responsiveness of the body changes with age:

1 Increased responsiveness while taking

• ACE-inhibitor, CCB (Ca channel blocker), coumarins.

• Digoxin and antiarrhythmics: alterations in Na/K-ATPase and Ca2+ channels lead to enhanced toxicity

• Opiates: may suppress respiration.

• Benzodiazepines: the probability of falls increases.

• Antidiabetic agents: impaired glucose counter-regulation predisposes the elderly to hypoglycemia.

• Antihypertensive agents:

- due to  baroreceptor sensitivity: orthostatic hypotension.

- due to  thirst: exsiccosis.

- due osmoreceptor dysfunction : hyponatremia.

(22)

Pharmacodynamic changes in the elderly: decreased responsiveness

2 Decreased responsiveness while taking

• Diuretics.

• Beta-blockers: the effect is slower due to an increased level of epinephrine.

• Beta-adrenoceptor agonists: lower sensitivity of the myocardium to catecholamines.

(23)

Main aspects of medication in the elderly

• Multimorbidity increases with age.

• The changes mentioned previously have influence on the drug effects in the body.

• Polypragmasy increases the number of side- effects and drug interactions.

• Compliance decreases with age.

• There is no real Evidence Based Medicine in the elderly, since they are not involved in

clinical trials.

(24)

Main aspects of medication in the elderly: Drug side effects

Medical care of the elderly involves a 2-3 times higher risk for side effects.

Their number is endless. Typical side effects:

• lack of appetite

• disturbance of gustatory sensation

• dryness in the mouth

• malabsorption (minerals, vitamins)

• iatrogenic incontinence (incontinentia urinae seu alvi)

• impaired cognitive functions

• gait disorders, falls

(25)

Drug side effects in numbers

• Regarding patients above the age of 65, iatrogenic

medication-associated disorders are responsible for 5-10%

of hospitalizations in Western-Europe .

• Above the age of 85 every 5th hospitalization is due to side effects of medication.

number of drugs risk for side effects

5 types of drug/day 4%

6-10 types of drug/day 10%

10-15 types of drug/day 28%

more than 16 types of drug/day 54%

• Simply decreasing the number of drugs may prevent harmful side effects without affecting the quality of life or the life span.

(26)

Main aspects of medication in the elderly: Drug interactions

In the long run the most dangerous drug combinations are the following:

• warfarin + NSAID, or sulphonamides , or macrolides, or quinolones, or phenytoin

• ACE inhibitors + K-sparing diuretics, (spironolactone)

• digoxin + amiodaron or verapamil

• theophyllines + quinolones.

(27)

Illness-medication problems

to which the elderly are susceptible because of their medical problems

Illness

Medication

Drug

interaction Drug

adverse

effect

(28)

“Start low, go slow!”

• Start with a small dose, increase the dose carefully.

• In case of unexplained deterioration of the patient’s condition, think about drug

interaction.

• In the elderly, quality of life is at least as

important as the therapeutic success.

Hivatkozások

KAPCSOLÓDÓ DOKUMENTUMOK

• Tyrosine-Kinase Associated Receptors: receptors that associate with proteins that have tyrosine kinase activity (Cytokine Receptors).. Receptor

• Regulates smooth muscle relaxation, platelet function, sperm metabolism, cell division and nucleic acid synthesis.. Nitroglycerin: treatment of coronary disease (Angina

• Ca 2+ -sensitive photoproteins: Aequorin (Aequoria victoria) – Emits blue light when binds Ca 2+. – First microinjected into target cell (eg. giant

development; Drosophila segmentation Nuclear hormone receptors Glucocorticoid receptor, estrogen receptor,. testosterone receptor, retinoic acid receptors Secondary

• EBF: early B-cell factor, B-cell fate determinant, turns on B- cell specific genes. • Pax5: in its absence cells are blocked at pro-B stage, self renew, broad

ZAP-70 is normally expressed in T cells and natural killer cells and has a critical role in the initiation of T-cell signaling. • ZAP-70 in B cells is used as a prognostic marker

• Cytokines: TNF, IL-1, IL-4, IL-5, IL-6, IL-13, MIP-1a, IL-3,

• After ligand binding, the tyrosine (Y) residue of the ITAM is phosphorylated by tyrosine kinases, and a signaling cascade is generated within the cell.. • An ITAM is present in